Synthesis of 213Bi-DOTATOC for peptide receptor a-therapy of GEP-NET patients refractory to β-therapy
Therapy with β-emitter labelled 90Y- or 177Lu-DOTATOC is a promising option for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, some patients become refractory to treatment with beta emitters. 213Bi, an α-emitter, has demonstrated the capability to break radioresistance to β-radiation in vitro. We report a method for the synthesis of 213Bi-DOTATOC (Bi-TOC) in clinical levels and give an interim analysis of an ongoing dose escalation study assessing the toxicity and efficacy of i.a. administered Bi-TOC.
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
APOSTOLIDIS Christos;
GIESEL Frederik;
MIER Walter;
HABERKORN Uwe;
KRATOCHWIL Clemens;
2013-06-13
SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
JRC80486
0029-5566,
www.nuklearmedizin-online.de,
https://publications.jrc.ec.europa.eu/repository/handle/JRC80486,
Additional supporting files
| File name | Description | File type | |
|---|
